Gilles Montalescot
Latest contributions
What an interventional cardiologist should know about anti-thrombotics
22 May 2025 – From EuroPCR 2025
This session provides comprehensive knowledge on anti-thrombotic management for interventional cardiologists, emphasizing effective inhibition during acute STEMI, latest evidence implementation for high bleeding risk patients, and customization of dual antiplatelet therapy in patients with high thrombotic and low bleeding risks through clinical cases and evidence-based recommendations.
Major Late-Breaking Trials from EuroPCR 2025
21 May 2025 – From EuroPCR 2025
Discover major late-breaking trials from EuroPCR 2025 in this session presenting pivotal study data. Highlights include meta-analyses from the PROTECTED TAVR and BHF PROTECT-TAVI studies, angiography versus physiology-guided PCI during TAVI (FAITAVI trial), and novel antiplatelet strategies following drug-coated stent implantation in acute coronary syndrome, with...
The future of STEMI care: a new treatment for bridging the gap from diagnosis to treatment
14 May 2024 – From EuroPCR 2024
Watch this session to delve into the crucial role of pre-hospital STEMI diagnosis and treatment. Gain insights into the significance of early intervention and explore previous facilitated PCI trials in STEMI. Additionally, learn about a promising new agent for pre-hospital STEMI treatment, offering potential advancements in...
PCR Spotlight: antithrombotic and anticoagulant treatment in the COVID-19 era
18 May 2020
D Capodanno, G Montalescot, and D Angiolillo discuss how to manage antithrombotic therapy in patients with COVID-19 undergoing interventional procedures.
